The ever-increasing enterprise capital funding for European life sciences corporations halted in 2022. With a roughly EUR 9.6bn quantity, the general financing for European life sciences corporations in 2022 decreased considerably in comparison with 2021 (EUR 13.6bn) by 28%.
Whereas within the first quarter, funding volumes roughly matched, from April onwards, the funding volumes in 2021 persistently outperformed these of 2022.Â
Based mostly on these observations, we count on more difficult fundraising campaigns for European healthcare corporations over the following few months.